Abattis Bioceuticals Corp Stock Performance
ATTBF Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Abattis Bioceuticals are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Abattis Bioceuticals Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental drivers, Abattis Bioceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
Begin Period Cash Flow | 4.1 M | |
Total Cashflows From Investing Activities | -11.5 M |
Abattis |
Abattis Bioceuticals Relative Risk vs. Return Landscape
If you would invest 0.01 in Abattis Bioceuticals Corp on August 26, 2024 and sell it today you would earn a total of 0.00 from holding Abattis Bioceuticals Corp or generate 0.0% return on investment over 90 days. Abattis Bioceuticals Corp is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Abattis, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
Risk |
Abattis Bioceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Abattis Bioceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Abattis Bioceuticals Corp, and traders can use it to determine the average amount a Abattis Bioceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
ATTBF |
Based on monthly moving average Abattis Bioceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Abattis Bioceuticals by adding Abattis Bioceuticals to a well-diversified portfolio.
Abattis Bioceuticals Fundamentals Growth
Abattis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Abattis Bioceuticals, and Abattis Bioceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Abattis Pink Sheet performance.
Return On Equity | -0.28 | |||
Return On Asset | -0.16 | |||
Operating Margin | (10.96) % | |||
Current Valuation | 4.08 M | |||
Shares Outstanding | 477.8 M | |||
Price To Earning | (5.83) X | |||
Price To Book | 0.38 X | |||
Price To Sales | 1.33 X | |||
Revenue | 356.88 K | |||
EBITDA | (2.9 M) | |||
Cash And Equivalents | 2.4 M | |||
Total Debt | 150.86 K | |||
Debt To Equity | 0.01 % | |||
Book Value Per Share | 0.02 X | |||
Cash Flow From Operations | 9.41 M | |||
Earnings Per Share | (0.01) X | |||
Total Asset | 19.26 M | |||
Retained Earnings | (10.13 M) | |||
Current Asset | 260 K | |||
Current Liabilities | 848 K | |||
About Abattis Bioceuticals Performance
By analyzing Abattis Bioceuticals' fundamental ratios, stakeholders can gain valuable insights into Abattis Bioceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Abattis Bioceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Abattis Bioceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada. ABATTIS BIOCEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Abattis Bioceuticals Corp performance evaluation
Checking the ongoing alerts about Abattis Bioceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Abattis Bioceuticals Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Abattis Bioceuticals generated a negative expected return over the last 90 days | |
Abattis Bioceuticals has some characteristics of a very speculative penny stock | |
Abattis Bioceuticals Corp has accumulated 150.86 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Abattis Bioceuticals Corp has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Abattis Bioceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Abattis Bioceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abattis Bioceuticals Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abattis to invest in growth at high rates of return. When we think about Abattis Bioceuticals' use of debt, we should always consider it together with cash and equity. | |
The entity reported the revenue of 356.88 K. Net Loss for the year was (3.04 M) with profit before overhead, payroll, taxes, and interest of 241.34 K. |
- Analyzing Abattis Bioceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Abattis Bioceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Abattis Bioceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Abattis Bioceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Abattis Bioceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Abattis Bioceuticals' pink sheet. These opinions can provide insight into Abattis Bioceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Abattis Pink Sheet analysis
When running Abattis Bioceuticals' price analysis, check to measure Abattis Bioceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abattis Bioceuticals is operating at the current time. Most of Abattis Bioceuticals' value examination focuses on studying past and present price action to predict the probability of Abattis Bioceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abattis Bioceuticals' price. Additionally, you may evaluate how the addition of Abattis Bioceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |